TW202114656A - 治療與s1p1 受體相關之病況的方法 - Google Patents

治療與s1p1 受體相關之病況的方法 Download PDF

Info

Publication number
TW202114656A
TW202114656A TW109134240A TW109134240A TW202114656A TW 202114656 A TW202114656 A TW 202114656A TW 109134240 A TW109134240 A TW 109134240A TW 109134240 A TW109134240 A TW 109134240A TW 202114656 A TW202114656 A TW 202114656A
Authority
TW
Taiwan
Prior art keywords
compound
certain embodiments
individual
administered
treatment
Prior art date
Application number
TW109134240A
Other languages
English (en)
Chinese (zh)
Inventor
可立瑞 泰 克提斯 倪言
黎賽特 瑪麗 雅可維多
Original Assignee
美商艾尼納製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商艾尼納製藥公司 filed Critical 美商艾尼納製藥公司
Publication of TW202114656A publication Critical patent/TW202114656A/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW109134240A 2019-10-01 2020-09-30 治療與s1p1 受體相關之病況的方法 TW202114656A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962909113P 2019-10-01 2019-10-01
US62/909,113 2019-10-01

Publications (1)

Publication Number Publication Date
TW202114656A true TW202114656A (zh) 2021-04-16

Family

ID=75337529

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109134240A TW202114656A (zh) 2019-10-01 2020-09-30 治療與s1p1 受體相關之病況的方法

Country Status (12)

Country Link
US (1) US20220347158A1 (https=)
EP (1) EP4037678A4 (https=)
JP (1) JP2022550458A (https=)
KR (1) KR20220074913A (https=)
CN (2) CN115038438A (https=)
AU (1) AU2020360413A1 (https=)
BR (1) BR112022005999A2 (https=)
CA (1) CA3156182A1 (https=)
IL (1) IL291654A (https=)
MX (1) MX2022003982A (https=)
TW (1) TW202114656A (https=)
WO (1) WO2021067506A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240134360A (ko) 2022-01-13 2024-09-09 아레나 파마슈티칼스, 인크. 호르몬 치료와 조합되어 s1p1 수용체-연관된 장애를 치료하는 데 사용하기 위한 에트라시모드

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8580841B2 (en) * 2008-07-23 2013-11-12 Arena Pharmaceuticals, Inc. Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
JP5856980B2 (ja) * 2010-01-27 2016-02-10 アリーナ ファーマシューティカルズ, インコーポレイテッド (R)−2−(7−(4−シクロペンチル−3−(トリフルオロメチル)ベンジルオキシ)−1,2,3,4−テトラヒドロシクロペンタ[b]インドール−3−イル)酢酸およびその塩の調製のためのプロセス
PL3242666T3 (pl) * 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
BR112017027656B1 (pt) * 2015-06-22 2023-12-05 Arena Pharmaceuticals, Inc. Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo
MX2019009843A (es) * 2017-02-16 2020-01-30 Arena Pharm Inc Compuestos y metodos para el tratamiento de la enfermedad inflamatoria intestinal con manifestaciones extraintestinales.

Also Published As

Publication number Publication date
AU2020360413A8 (en) 2022-04-21
WO2021067506A1 (en) 2021-04-08
IL291654A (en) 2022-05-01
BR112022005999A2 (pt) 2022-07-12
US20220347158A1 (en) 2022-11-03
CN119280227A (zh) 2025-01-10
KR20220074913A (ko) 2022-06-03
CN115038438A (zh) 2022-09-09
EP4037678A1 (en) 2022-08-10
EP4037678A4 (en) 2023-11-29
CA3156182A1 (en) 2021-04-08
JP2022550458A (ja) 2022-12-01
AU2020360413A1 (en) 2022-04-14
MX2022003982A (es) 2022-07-12

Similar Documents

Publication Publication Date Title
EP3908276B1 (en) Methods of treating conditions related to the s1p1 receptor
US11478448B2 (en) Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
JP2017200926A (ja) 第一選択の抗TNEα療法に失敗したクローン病患者を治療するためのラキニモドの使用
KR20160148050A (ko) 라퀴니모드를 이용한 크론병의 치료
KR20150135552A (ko) 라퀴니모드를 이용한 루푸스 신장염의 치료
KR20240148425A (ko) Cns-관련 장애의 치료를 위한 신경활성 스테로이드
US20220023258A1 (en) Methods of treating conditions related to the s1p1 receptor
TW202341996A (zh) 用於治療腸胃疾病或病狀之神經活性類固醇
WO2022099150A1 (en) Methods of treating conditions related to the s1p1 receptor
JP2023502355A (ja) S1p1受容体に関連する状態を処置する方法
TW202114656A (zh) 治療與s1p1 受體相關之病況的方法
KR102958419B1 (ko) S1p₁ 수용체와 관련된 병태의 치료 방법
HK40116740A (zh) 治疗与s1p1受体有关的病况的方法
HK40063670B (en) Methods of treating conditions related to the s1p1 receptor
HK40063670A (en) Methods of treating conditions related to the s1p1 receptor
WO2023214312A1 (en) Methods of treating atopic dermatitis with etrasimod
AU2023203085A1 (en) Methods of treating conditions related to the S1P1 receptor
HK40116488A (zh) 治疗与s1p1受体有关的病况的方法
WO2026043678A1 (en) Bexicaserin for use in a method of treatment of seizure-induced sudden unexpected death in epilepsy
WO2023159035A1 (en) Neuroactive steroids for treatment of cns-related disorders
TW202339718A (zh) 治療方法
HK40109901A (zh) 与激素治疗组合的用於治疗s1p1受体相关病症的伊曲莫德